The U.S. Food and Drug Administration authorized NeuroLutions to market its brain-computer interface device in April of this year. The Santa Cruz, CA company was founded in 2007, has research and funding ties to St. Louis. CrunchBase says it has brought in a combined $1.3M in VC from Ascension Ventures, Prolog Ventures, BioGenerator and an earlier seed round by St. Louis Arch Angels.

The company is trying to build a platform to spin out devices that use their brain-computer interface, but this first device specifically facilitates muscle re-education for adult stroke survivors with upper extremity (hand, wrist, arm) disability.

The IpsiHand system uses non-invasive electroencephalography electrodes instead of using an implanted electrode to record brain activity. The data is wirelessly conveyed to a tablet for analysis (to gauge intent) and a signal is sent to a wireless electronic hand brace to move the patient’s hand. The device is prescription-only and is intended to be part of rehabilitation therapy.

Links:

NeuroLutions

FDA release